137 related articles for article (PubMed ID: 12475838)
1. Costs of COPD in Sweden according to disease severity.
Jansson SA; Andersson F; Borg S; Ericsson A; Jönsson E; Lundbäck B
Chest; 2002 Dec; 122(6):1994-2002. PubMed ID: 12475838
[TBL] [Abstract][Full Text] [Related]
2. Health economic costs of COPD in Sweden by disease severity--has it changed during a ten years period?
Jansson SA; Backman H; Stenling A; Lindberg A; Rönmark E; Lundbäck B
Respir Med; 2013 Dec; 107(12):1931-8. PubMed ID: 23910072
[TBL] [Abstract][Full Text] [Related]
3. The costs of exacerbations in chronic obstructive pulmonary disease (COPD).
Andersson F; Borg S; Jansson SA; Jonsson AC; Ericsson A; Prütz C; Rönmark E; Lundbäck B
Respir Med; 2002 Sep; 96(9):700-8. PubMed ID: 12243316
[TBL] [Abstract][Full Text] [Related]
4. Cost differences for COPD with and without physician-diagnosis.
Jansson SA; Lindberg A; Ericsson A; Borg S; Rönmark E; Andersson F; Lundbäck B
COPD; 2005 Dec; 2(4):427-34. PubMed ID: 17147008
[TBL] [Abstract][Full Text] [Related]
5. The economic consequences of asthma among adults in Sweden.
Jansson SA; Rönmark E; Forsberg B; Löfgren C; Lindberg A; Lundbäck B
Respir Med; 2007 Nov; 101(11):2263-70. PubMed ID: 17689234
[TBL] [Abstract][Full Text] [Related]
6. Resource use and costs in a Swedish cohort of patients with Parkinson's disease.
Hagell P; Nordling S; Reimer J; Grabowski M; Persson U
Mov Disord; 2002 Nov; 17(6):1213-20. PubMed ID: 12465059
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.
Price D; Keininger D; Costa-Scharplatz M; Mezzi K; Dimova M; Asukai Y; Ställberg B
Respir Med; 2014 Dec; 108(12):1786-93. PubMed ID: 25307414
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting chronic obstructive pulmonary disease (COPD)-related costs: a multivariate analysis of a Swedish COPD cohort.
Gerdtham UG; Andersson LF; Ericsson A; Borg S; Jansson SA; Rönmark E; Lundbäck B
Eur J Health Econ; 2009 May; 10(2):217-26. PubMed ID: 18853206
[TBL] [Abstract][Full Text] [Related]
9. Hospitalization Due to Co-Morbid Conditions is the Main Cost Driver Among Subjects With COPD-A Report From the Population-Based OLIN COPD Study.
Jansson SA; Backman H; Rönmark E; Lundbäck B; Lindberg A
COPD; 2015 Aug; 12(4):381-9. PubMed ID: 25415366
[TBL] [Abstract][Full Text] [Related]
10. Cost impact of COPD in Japan: opportunities and challenges?
Nishimura S; Zaher C
Respirology; 2004 Nov; 9(4):466-73. PubMed ID: 15612957
[TBL] [Abstract][Full Text] [Related]
11. Comparative study on medical utilization and costs of chronic obstructive pulmonary disease with good lung function.
Lim JU; Kim K; Kim SH; Lee MG; Lee SY; Yoo KH; Lee SH; Jung KS; Rhee CK; Hwang YI
Int J Chron Obstruct Pulmon Dis; 2017; 12():2711-2721. PubMed ID: 28979113
[TBL] [Abstract][Full Text] [Related]
12. Healthcare costs of COPD in Italian referral centres: a prospective study.
Koleva D; Motterlini N; Banfi P; Garattini L;
Respir Med; 2007 Nov; 101(11):2312-20. PubMed ID: 17681461
[TBL] [Abstract][Full Text] [Related]
13. The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991.
Jacobson L; Hertzman P; Löfdahl CG; Skoogh BE; Lindgren B
Respir Med; 2000 Mar; 94(3):247-55. PubMed ID: 10783936
[TBL] [Abstract][Full Text] [Related]
14. The societal cost of schizophrenia in Sweden.
Ekman M; Granstrom O; Omerov S; Jacob J; Landen M
J Ment Health Policy Econ; 2013 Mar; 16(1):13-25. PubMed ID: 23676412
[TBL] [Abstract][Full Text] [Related]
15. The SCOPE study: health-care consumption related to patients with chronic obstructive pulmonary disease in France.
Detournay B; Pribil C; Fournier M; Housset B; Huchon G; Huas D; Godard P; Voinet C; Chanal I; Jourdanne C; Durand-Zaleski I;
Value Health; 2004; 7(2):168-74. PubMed ID: 15164806
[TBL] [Abstract][Full Text] [Related]
16. Anemia in chronic obstructive pulmonary disease: epidemiology and economic implications.
Shorr AF; Doyle J; Stern L; Dolgitser M; Zilberberg MD
Curr Med Res Opin; 2008 Apr; 24(4):1123-30. PubMed ID: 18331668
[TBL] [Abstract][Full Text] [Related]
17. Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD.
Ke X; Marvel J; Yu TC; Wertz D; Geremakis C; Wang L; Stephenson JJ; Mannino DM
Int J Chron Obstruct Pulmon Dis; 2016; 11():1689-703. PubMed ID: 27555759
[TBL] [Abstract][Full Text] [Related]
18. Cost analysis of chronic obstructive pulmonary disease in a tertiary care setting in Taiwan.
Chiang CH
Respirology; 2008 Sep; 13(5):689-94. PubMed ID: 18513247
[TBL] [Abstract][Full Text] [Related]
19. Social economic costs of COPD in Extremadura (Spain): an observational study.
Merino M; Villoro R; Hidalgo-Vega Á; Carmona C
Int J Chron Obstruct Pulmon Dis; 2018; 13():2501-2514. PubMed ID: 30174420
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries.
Nielsen R; Kankaanranta H; Bjermer L; Lange P; Arnetorp S; Hedegaard M; Stenling A; Mittmann N
Respir Med; 2013 Nov; 107(11):1709-21. PubMed ID: 23856511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
